Perspective advances VMT-α-NET to 6.0 mCi dose, raises $175M, extends runway to late 2027

Filed March 16, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 26, 2025 · ~1 min read

Key Changes

• high

  VMT-α-NET Cohort 2 closed at 46 patients with 76% progression-free survival and 39% response rate (8 confirmed, 1 initial); Cohort 3 opened at 6.0 mCi dose with 16 patients treated and DLT assessment complete as of Feb 2026.

  MD&A: VMT-α-NET Clinical Progress verify on EDGAR →
• high

  Company raised $175M gross proceeds in Feb 2026 underwritten offering, extending cash runway from late 2026 to late 2027 despite year-over-year cash decline from $226.9M to $144.7M.

  MD&A: Capital and Runway verify on EDGAR →
• high

  PSV359 advanced from IND filing to active Phase 1 dosing: FDA cleared trial in Q1 2025, first patient dosed April 2025, and 8 patients treated across two dose cohorts (2.5 mCi and 5.0 mCi) as of Feb 2026.

  MD&A: PSV359 Pipeline verify on EDGAR →